Viruses and the Threat of Bioterrorism

Abstract

Viruses can be used by both States and terrorists as biological weapons, but using them on a wide scale requires considerable technical knowledge and facilities. Many viruses can be spread by aerosols, potentially infecting large populations. Various agents have been proposed as potential weapons, but smallpox has received the greatest attention and was successfully weaponised by the Soviet Union. Smallpox vaccine has been stockpiled and new drugs and vaccines developed. Other potential agents suggested in the literature include Ebola and Marburg viruses, although these are very difficult to produce in quantity. Terrorists could however use any agent and rarely follow textbook scenarios. In response to the threat of bioterrorism a substantial research and public health infrastructure has been created, which could be useful in dealing with natural events. The main defence is education of clinicians and the public as the greatest effect of these weapons is fear and panic.

Key Concepts:

  • Viruses are potential biological weapons, and many viruses are infectious by the aerosol route even if they are normally transmitted by vectors.

  • Smallpox has received most attention as a potential biological threat.

  • Knowledge, skills, research and public health infrastructure are the best defence for bioterrorism.

  • Standard principles of infection control and public health apply to bioterrorist incidents.

  • Nature is the greatest bioterrorist and the infrastructure developed for deliberate acts supports real events.

Keywords: bioterrorism; smallpox; haemorrhagic fever; preparedness; vaccine; antiviral; aerosol

Figure 1.

The outbreak of smallpox in the former Yugoslavia from a single case who infected his immediate friends and carers in 1972. The exact total of cases is unknown, but there were at least 165 people infected. Redrawn with permission from Figure 23.7 in Fenner et al. .

Figure 2.

Renwick Smallpox hospital on Roosevelt Island, East River, New York. Isolation hospitals were a key part of the control of infectious diseases in the late nineteenth and early twentieth centuries, and smallpox hospitals were maintained in England until the 1970s.

Figure 3.

UK stocks of freeze dried sheep's lymph vaccine for smallpox. These 50 dose ampoules were reconstituted with the fluid in the double ended ampoule and administered with a bifurcated needle.

Figure 4.

A smallpox “take” reaction. Note the forming vesicle which contains live vaccinia virus.

close

References

Alibek K and Handelman S (1999) Biohazard. The Chilling True Story of the Largest Covert Biological Weapons Program in the World. New York: Random House.

Anon (1979) Which is the factual basis, in theory and clinical practice, for the use of vaccinia immune globulin for the prevention or attenuation of complications of smallpox vaccination? Vox Sang 36(2): 121–128.

Anon (2011) Smallpox should be saved. Nature 469(7330): 265.

Borio L, Inglesby T, Peters CJ et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. Journal of American Medical Association 287(18): 2391–2405.

Casadevall A and Relman DA (2010) Microbial threat lists: obstacles in the quest for biosecurity? Nature Reviews Microbiology 8(2): 149–154.

Conybeare ET (1964) Illnesses attributed to smallpox vaccination, 1951–60. II. Illnesses reported as affecting the central nervous system. Monthly Bulletin of the Ministry of Health and the Public Health Laboratory Services 23: 150–160.

Dias MB, Reyes‐Gonzalez L, Veloso FM and Casman EA (2010) Effects of the USA PATRIOT Act and the 2002 Bioterrorism Preparedness Act on select agent research in the United States. Proceedings of National Academy of Sciences of the USA 107(21): 9556–9561.

Dick G (1973) Complications of smallpox vaccination in the United Kingdom. Symposium Series on Immunobiological Standard 19: 205–215.

Douglas RG Jr, Lynch EC and Spira M (1972) Treatment of progressive vaccinia. Use of methisazone, vaccinia immune serum globulin, and surgical debridement. Archives of Internal Medicine 129(6): 980–983.

Earl PL, Americo JL, Wyatt LS et al. (2008) Rapid protection in a monkeypox model by a single injection of a replication‐deficient vaccinia virus. Proceedings of National Academy of Sciences of the USA 105(31): 10889–10894.

Feery BJ (1976) The efficacy of vaccinial immune globulin. A 15‐year study. Vox Sang 31(suppl. 1): 68–76.

Fenner F, Henderson DA, Arita I, JeZek Z and Ladnyi ID (1988) Smallpox and Its Eradication. Geneva: World Health Organisation.

Gottron F (2010). Project BioShield: Authorities, Appropriations, Acquisitions, and Issues for Congress. C. R. Service. Washington, Congressional Research Service.

Henderson DA, Inglesby TV, Bartlett JG et al. (1999) Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. Journal of American Medical Association 281(22): 2127–2137.

Huggins J, Goff A, Hensley L et al. (2009) Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST‐246. Antimicrobial Agents and Chemothererapy 53(6): 2620–2625.

Jacobs BL, Langland JO, Kibler KV et al. (2009) Vaccinia virus vaccines: past, present and future. Antiviral Research 84(1): 1–13.

Jaroszynska‐Weinberger B (1970) Treatment with methisazone of complications following smallpox vaccination. Archives of Diseases in Childhood 45(242): 573–580.

Jaroszynska‐Weinberger B and Meszaros J (1966) A comparison of the protective effect of methisazone and a hyperimmune antivaccinial gamma‐globulin in primary smallpox vaccination carried out in the presence of contraindications. Lancet 1(7444): 948–951.

Johnson BF, Kanatani Y, Fujii T et al. (2011) Serological responses in humans to smallpox vaccine LC16m8. Journal of General Virology. 92(10): 2405–2410.

Jordan R, Goff A, Frimm A et al. (2009) ST‐246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrobial Agents Chemotherapy 53(5): 1817–1822.

Kennedy JS and Greenberg RN (2009) IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Review of Vaccines 8(1): 13–24.

Koprowski H and Cox HR (1947) Human laboratory infection with Venezuelan equine encephalomyelitis virus; report of four cases. New England Journal of Medicine 236(18): 647–654.

Lane JM, Ruben FL, Neff JM and Millar JD (1969) Complications of smallpox vaccination, 1968. New England Journal of Medicine 281(22): 1201–1208.

Lukaszewski RA and Brooks TJ (2000) Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. Journal of Virology 74(11): 5006–5015.

Nalca A, Hatkin JM, Garza NL et al. (2008) Evaluation of orally delivered ST‐246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Research 79(2): 121–127.

Neff JM, Lane JM, Pert JH et al. (1967) Complications of smallpox vaccination. I. National survey in the United States, 1963. New England Journal of Medicine 276(3): 125–132.

O'Brien LM, Underwood‐Fowler CD, Goodchild SA, Phelps AL and Phillpotts RJ (2009) Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains. Virology Journal 6: 206.

Paessler S and Weaver SC (2009) Vaccines for Venezuelan equine encephalitis. Vaccine 27(suppl. 4): D80–D85.

Phillpotts RJ (2006) Venezuelan equine encephalitis virus complex‐specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Research 120(1–2): 107–112.

Phillpotts RJ, Jones LD and Howard SC (2002) Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 20(11–12): 1497–1504.

Quenelle DC, Buller RM, Parker S et al. (2007) Efficacy of delayed treatment with ST‐246 given orally against systemic orthopoxvirus infections in mice. Antimicrobial Agents and Chemotherapy 51(2): 689–695.

Roffey R, Tegnell A and Elgh F (2002) Biological warfare in a historical perspective. Clinical Microbiology and Infection 8(8): 450–454.

Rusnak JM, Kortepeter MG, Hawley RJ et al. (2004) Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecurity and Bioterrorism 2(4): 281–293.

Russell PK (2007) Project BioShield: what it is, why it is needed, and its accomplishments so far. Clinical Infectious Diseases 45(suppl. 1): S68–S72.

Sbrana E, Jordan R, Hruby DE et al. (2007) Efficacy of the antipoxvirus compound ST‐246 for treatment of severe orthopoxvirus infection. American Journal of Tropical Medicine and Hygiene 76(4): 768–773.

Smith SK, Olson VA, Karem KL et al. (2009) In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrobial Agents and Chemotherapy 53(3): 1007–1012.

Vogel P, Fritz DL, Kuehl K, Davis KJ and Geisbert T (1997) The agents of biological warfare. Journal of American Medical Association 278(5): 438–439.

Further Reading

CDC. Bioterrorism Agents/Diseases. From http://www.bt.cdc.gov/agent/agentlist‐category.asp.

Koblenz GD (2009) Living Weapons: Biological Warfare and International Security (Cornell Studies in Security Affairs). New York: Cornell University Press.

Mandell GL, Bennett JE and Dolin R (2009) Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone.

Regis E (2000) The Biology of Doom. New York: Owl Books.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Brooks, Timothy JG(Feb 2012) Viruses and the Threat of Bioterrorism. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0003368.pub2]